NCT02155829View on ClinicalTrials.gov

Safety Study of Riluzole to Treat Post-traumatic Stress Disorder (PTSD)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

October 30, 2017

Study Completion Date

November 30, 2017

Conditions
PTSD
Interventions
DRUG

Riluzole

DRUG

Placebo (for Riluzole)

Trial Locations (2)

13210

Syracuse VA Medical Center, Center for Integrated Healthcare (116C), Syracuse

20814

Walter Reed National Military Medical Center, Bethesda

All Listed Sponsors
collaborator

U.S. Army Medical Research and Development Command

FED

lead

Uniformed Services University of the Health Sciences

FED

NCT02155829 - Safety Study of Riluzole to Treat Post-traumatic Stress Disorder (PTSD) | Biotech Hunter | Biotech Hunter